Zensar Technologies (504067) Q4 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 25/26 earnings summary
7 May, 2026Executive summary
Delivered resilient revenue and profitability growth for FY 2026, driven by AI-native offerings, offshore-led volume, and a mega deal win, with 85% of workforce AI-certified and multiple high-value AI-led wins.
Achieved highest-ever annualized order book and robust cash position, with Q4 FY26 revenue at $158.4M, up 1% YoY, and PAT margin at 14.4%, a 50 bps sequential increase.
FY26 total revenue was $643.7M, growing 3.1% YoY, and PAT margin improved by 120 bps to 13.5%.
Customer satisfaction and employee retention reached industry-leading levels, with attrition at 9.8% for Q4 and FY26.
Audited standalone and consolidated financial results for FY26 were approved with unmodified auditor opinions.
Financial highlights
FY26 consolidated revenue: $643.7M (₹56,874 million), up 3.1% YoY in USD and 7.7% YoY in INR; Q4 revenue: $158.4M, up 1% YoY.
FY26 profit after tax: $87.2M (₹7,746 million), up 13.6% YoY; PAT margin for Q4: 14.4%, up 50 bps sequentially.
Net cash and equivalents: $319.5M (₹4,163 million), up 10% YoY.
Order book at all-time high: $401.8M for Q4, up 122.9% sequentially; full-year order book $912.7M, up 17.8% YoY.
Final dividend of $12.6/share (INR 12.60 per share), total dividend 750% of face value, subject to AGM approval.
Outlook and guidance
No de-growth expected in Q1 FY27; growth anticipated in EU, South Africa, BFSI, and MCS segments.
Margin guidance remains mid-teens (14%-16%) for FY27, with some pressure in Q1 and Q2 due to large deal transition costs.
Full ramp-up of mega deal revenue expected by Q3 FY27; management highlights robust order book growth and continued AI-led investments.
Company continues to monitor regulatory changes, especially regarding new Labour Codes.
Latest events from Zensar Technologies
- Q3 FY26 saw revenue and margin growth, strong order book, and continued AI-driven investments.504067
Q3 25/2623 Jan 2026 - Q2 FY25 saw record order book, margin expansion, and strong BFSI/healthcare growth.504067
Q2 24/2519 Jan 2026 - Q3 FY25 delivered 8.6% revenue growth, margin expansion, record order book, and key acquisition.504067
Q3 24/2510 Jan 2026 - Q4 FY25 saw 6.3% YoY revenue growth, 13% PAT margin, and a final dividend of INR 11 per share.504067
Q4 24/2527 Dec 2025 - Q1 FY26 revenue up 4.9% YoY to $162M, with strong margins and robust AI-driven order wins.504067
Q1 25/2625 Nov 2025 - Q2 revenue up 4.2% YoY to $162.8M, with margin gains, AI momentum, and TMT headwinds.504067
Q2 25/262 Nov 2025